Amendments for: 172-2021-2022-Q4-988469

Agreement Value: $97,900.00
Agreement: AI for drug design – chemical synthesis (988469). Mar 31, 2022 - Mar 31, 2024
Description:

Designing a drug to treat a specific disease type is a highly challenging exercise due to breadth of the molecular search space and having a limited understanding about many diseases of interest. The successful discovery of a medicine for a target disease (gene/protein/pathway) usually takes many years and is associated with a very significant investment by private pharmaceutical organization, which in turn tends to result in an unaffordable price of medicines in the Canadian and global markets. The emergence of significant biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provides an unprecedented opportunity for automatic design of new drugs at a much faster pace and at a much lower cost, igniting hopes to discover drugs for diseases where no medicines currently exist. In this project researchers will aim to develop a data and AI-driven drug design platform/pipeline for precise and effective treatment of cancers and complex diseases.

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Organization: National Research Council Canada
Recipient: University of Ottawa (Academia)
Location: Ottawa, Ontario, CA K1N 6N5
Type: Grant
Additional Information:

This agreement has been amended 1 time(s). The end date of this agreement has been modified by 365 days.

Federal Riding Name: Ottawa–Vanier (35078)
Program Name: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code: 541710

Agreement Value:
Agreement: AI for drug design – chemical synthesis - Mar 31, 2024
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:

This agreement has been amended 1 time(s). The end date of this agreement has been modified by 365 days.

Agreement Value: $97,900.00
Agreement: AI for Drug Design – Chemical Synthesis (988469). Mar 31, 2022 - Mar 31, 2023
Description:

Designing a drug to treat a specific disease type is a highly challenging exercise due to breadth of the molecular search space and having a limited understanding about many diseases of interest. The successful discovery of a medicine for a target disease (gene/protein/pathway) usually takes many years and is associated with a very significant investment by private pharmaceutical organization, which in turn tends to result in an unaffordable price of medicines in the Canadian and global markets. The emergence of significant biochemical and high-throughput genomic data acquisition techniques and the rise of advanced artificial intelligence paradigms provides an unprecedented opportunity for automatic design of new drugs at a much faster pace and at a much lower cost, igniting hopes to discover drugs for diseases where no medicines currently exist. In this project researchers will aim to develop a data and AI-driven drug design platform/pipeline for precise and effective treatment of cancers and complex diseases.

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Organization: National Research Council Canada
Recipient: University of Ottawa (Academia)
Location: Ottawa, Ontario, CA K1N 6N5
Type: Grant
Federal Riding Name: Ottawa–Vanier (35078)
Program Name: Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code: 541710